Age-stratified adverse-event reporting signals of seven ALK/ROS1 tyrosine kinase inhibitors in FAERS: a disproportionality and time to onset study
- DOI
- 10.3389/fphar.2026.1891628
- Published
- 2026-09-07
- Container
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fphar.2026.1891628,
title = {Age-stratified adverse-event reporting signals of seven ALK/ROS1 tyrosine kinase inhibitors in FAERS: a disproportionality and time to onset study},
author = {Yongjian Liu and Yingyu Yu and Yige Yu and Xingjun Huang and Hao Zhong},
year = {2026},
journal = {Frontiers in Pharmacology},
doi = {10.3389/fphar.2026.1891628},
url = {https://doi.org/10.3389/fphar.2026.1891628}
}RIS
TY - JOUR TI - Age-stratified adverse-event reporting signals of seven ALK/ROS1 tyrosine kinase inhibitors in FAERS: a disproportionality and time to onset study AU - Yongjian Liu AU - Yingyu Yu AU - Yige Yu AU - Xingjun Huang AU - Hao Zhong PY - 2026 JO - Frontiers in Pharmacology DO - 10.3389/fphar.2026.1891628 UR - https://doi.org/10.3389/fphar.2026.1891628 ER -
APA
Liu, Y., Yu, Y., Yu, Y., Huang, X., & Zhong, H. (2026). Age-stratified adverse-event reporting signals of seven ALK/ROS1 tyrosine kinase inhibitors in FAERS: a disproportionality and time to onset study. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2026.1891628
Source records
- crossref · retrieved 2026-09-25T23:28:49.837Z